THERAPY DOSSIER · th-f1489fd2f0d6

Perampanel

Drug · Glutamate receptor ionotropic AMPA antagonist

No trauma translation Suggest a correction

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: Glutamate receptor ionotropic AMPA antagonist
Target: CHEMBL2096670
Injury models: TBI
Reported indication: Adjunctive treatment of partial-onset seizures and primary generalized tonic-clonic seizures (epilepsy); FDA-approved 2012 (Fycompa)
First approval: 2012
Development stage: Approved for epilepsy; status epilepticus/acute use off-label; boxed warning
ChEMBL record: CHEMBL1214124 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: Perampanel; Fycompa; E-2007; E2007; ER-155055-90
Note: Not recorded

Clinical trials 11

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT04417907 ↗PHASE4terminated

Effects of Titration Rate on Cognitive/Behavioral Side Effects of Perampanel

Epilepsy

Enrolment: 29 · Results not recorded

NCT00360412 ↗PHASE3terminated

Long-term E2007 Adjunctive in Levodopa-treated Parkinson's With Motor Fluctuations

Parkinson's Disease

Enrolment: 997 · Results not recorded

NCT04309721 ↗PHASE3terminated

Add-on Perampanel in Focal Motor Status Epilepticus

Epilepticus; Status, Focal Motor

Enrolment: 1 · Results not recorded

NCT00592904 ↗PHASE2/PHASE3completed

Long-term E2007 (Perampanel) in Painful Diabetic Neuropathy or Post-Herpetic Neuralgia

Neuralgia

Enrolment: 262 · Results not recorded

NCT03780907 ↗PHASE2completed

Tolerability/Safety/PK of E2007 in Epilepsy With Partial/Generalised Seizures

Epilepsy

Enrolment: 18 · Results not recorded

NCT03754582 ↗PHASE2completed

Safety of IV Perampanel as Substitute for Oral Tablet in Seizures

Epilepsy · Seizures

Enrolment: 21 · Results not recorded

NCT06450236 ↗PHASE1completed

Bioequivalence of Perampanel 10 mg vs Fycompa 10 mg (fasting)

Epilepsy

Enrolment: 30 · Results not recorded

NCT03636958 ↗NAwithdrawn

Perampanel in Combination in Glioma-refractory Epilepsy

Refractory Epilepsy

Enrolment: 0 · Results not recorded

NCT02307578 ↗NAno longer available

Extended Access Program (EAP) for Perampanel

Primary Generalized Tonic-Clonic or Partial Onset Seizures · Lennox Gastaut Syndrome

Enrolment not recorded · Results not recorded

NCT03059329 ↗NAcompleted

Long-term Treatment With Fycompa Tablets in Adult Epilepsy

Partial Seizures · Primary Generalized Tonic-clonic Seizures

Enrolment: 3809 · Results not recorded

NCT05756621 ↗NAcompleted

Dual Ketamine+Perampanel in Super-refractory Status Epilepticus After Cardiac Arrest

Status Epilepticus · Cardiac Arrest

Enrolment: 84 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32027929 ↗2020Reported benefit

Acute administration of perampanel, an AMPA receptor antagonist, reduces cognitive impairments after traumatic brain injury in rats.

RatTBIFluid percussionSprague-DawleyMaleGiven either before or after injury (acute administration)

Model: Lateral fluid percussion injury, producing both focal and diffuse traumatic brain injury

Pre-injury or post-injury perampanel attenuated the injury-induced rise in the pro-apoptotic bax to bcl-xL ratio in the hippocampus and reduced impairments in learning and memory and in reward-seeking behaviour. Only male rats were studied, so sex differences remain undetermined.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.

Loading the evidence…